-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Lowered to $23 at H.C. Wainwright
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
-
-
-
-
-
-
FDA aligns with Regenxbio on path to refile MPS II gene therapy BLA
-
-
-
-
-
-
-
REGENXBIO reports interim data for Duchenne gene therapy RGX-202
-
-
-
-
-
-
-
Regenxbio (RGNX) Misses Q4 EPS by 58c
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
-
-
-
-
-
-
BofA top picks in biotech as sector heading for recovery in 2026
-
468,200 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

